Tuesday, August 6, 2024

More Immunotherapy Options Approved for Treating Endometrial Cancer - Cancer Currents Blog

Having trouble viewing this email? View it as a Web page.
Latest from Cancer Currents
08/06/2024
People with advanced endometrial cancer now have new FDA-approved treatment options: pembrolizumab and durvalumab, paired with chemotherapy, for tumors with a genetic change called mismatch repair deficiency. The agency also expanded the approved uses of dostarlimab for the disease.
Read the Story

You are subscribed to the latest posts from Cancer Currents: An NCI Cancer Research Blog from the National Cancer Institute. Update your subscriptions.

Bookmark and Share

This email was sent to edwardlorilla1986.paxforex@blogger.com using GovDelivery Communications Cloud on behalf of: National Cancer Institute · BG 9609 MSC 9760 · 9609 Medical Center Drive · Bethesda, MD 20892 GovDelivery logo

No comments:

Post a Comment

⏰[Trading Live NOW] Unlock Top Spread Strategies: FDX Earnings & FOMC Insights - Join Our Webinar!

Trader we are trading, join us! You receive this email, because you signed up to get email from YellowTunnel newsletter on 12/11/20.  ...